
Dapagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes, can improve glycemic control and attenuate weight gain associated with insulin therapy in patients with type 1 diabetes (T1D) without increasing hypoglycemic risk, as demonstrated in the DEPICT‐2 study. We examined the long‐term efficacy and safety of dapagliflozin in the Japanese sub‐population of DEPICT‐2.
Like
Save
Share